These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9926654)

  • 1. Medicare's end-stage renal disease program: current status and future prospects.
    Nissenson AR; Rettig RA
    Health Aff (Millwood); 1999; 18(1):161-79. PubMed ID: 9926654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National health insurance: lessons from the United States experiment.
    Derrick FW; Scott CE
    Health Care Manage Rev; 1995; 20(3):55-63. PubMed ID: 7591752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The direction of end-stage renal disease reimbursement in the United States.
    Lockridge RS
    Semin Dial; 2004; 17(2):125-30. PubMed ID: 15043614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caring for ESRD patients.
    Andriote JM
    Healthplan; 1998; 39(4):33-5. PubMed ID: 10351321
    [No Abstract]   [Full Text] [Related]  

  • 5. The social contract and the treatment of permanent kidney failure.
    Rettig RA
    JAMA; 1996 Apr; 275(14):1123-6. PubMed ID: 8601933
    [No Abstract]   [Full Text] [Related]  

  • 6. Accountable care organizations and ESRD: the time has come.
    Nissenson AR; Maddux FW; Velez RL; Mayne TJ; Parks J
    Am J Kidney Dis; 2012 May; 59(5):724-33. PubMed ID: 22459132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Financing of end-stage renal disease care: past, present, and future.
    Farley DO
    Adv Ren Replace Ther; 1994 Apr; 1(1):24-31. PubMed ID: 7641085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The organization and financing of kidney dialysis and transplant care in the United States of America.
    Hirth RA
    Int J Health Care Finance Econ; 2007 Dec; 7(4):301-18. PubMed ID: 17602296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicare HMOs reveal unique contracting strategies for new ESRD risk demonstration.
    Public Sect Contract Rep; 1997 May; 3(5):74-6. PubMed ID: 10174874
    [No Abstract]   [Full Text] [Related]  

  • 10. The success of medicare's end-stage renal-disease program: the case for profits and the private marketplace.
    Lowrie EG; Hampers CL
    N Engl J Med; 1981 Aug; 305(8):434-8. PubMed ID: 7019710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicare's ESRD program, Part 2: Transplantation.
    Long HW; Lauve RM
    Physician Exec; 1989; 15(3):31-3. PubMed ID: 10313122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. End-stage renal disease therapy: an American success story.
    Friedman EA
    JAMA; 1996 Apr; 275(14):1118-22. PubMed ID: 8601932
    [No Abstract]   [Full Text] [Related]  

  • 13. Medicare Program; End-Stage Renal Disease Prospective Payment System, Coverage and Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program Bid Surety Bonds, State Licensure and Appeals Process for Breach of Contract Actions, Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program and Fee Schedule Adjustments, Access to Care Issues for Durable Medical Equipment; and the Comprehensive End-Stage Renal Disease Care Model. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2016 Nov; 81(214):77834-969. PubMed ID: 27905888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Big Data in the Development and Evaluation of US Dialysis Care.
    Erickson KF; Qureshi S; Winkelmayer WC
    Am J Kidney Dis; 2018 Oct; 72(4):560-568. PubMed ID: 29921451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A quarter century of medicare expenditures for ESRD.
    Eggers PW
    Semin Nephrol; 2000 Nov; 20(6):516-22. PubMed ID: 11111852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. End-stage renal disease, managed care, and capitation: implications for the renal community.
    Rubin RJ; Gaylin DS; Shapiro JR
    Adv Ren Replace Ther; 1997 Oct; 4(4):306-13. PubMed ID: 9356682
    [No Abstract]   [Full Text] [Related]  

  • 17. The dialysis facility of the future: the financial and social environment.
    Steinman TI
    Semin Nephrol; 1997 Jul; 17(4):298-305. PubMed ID: 9241715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified capitation and treatment incentives for end stage renal disease.
    Farley DO; Carter GM; Kallich JD; Lucas TW; Spritzer KL
    Health Care Financ Rev; 1996; 17(3):129-42. PubMed ID: 10158726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicare's bloat is an opportunity for business.
    Kleinke JD
    Bus Health; 1995 May; 13(5):72. PubMed ID: 10164500
    [No Abstract]   [Full Text] [Related]  

  • 20. Reduction in ESRD reimbursement rate: identifying research priorities and quality indicators.
    Parker J
    ANNA J; 1990 Apr; 17(2):147-54. PubMed ID: 2183724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.